TMCnet News
Cytel breaks new ground in adaptive designs with East® 6.4 releaseCytel Inc., a global provider of adaptive trial design software, statistical consultancy, and clinical research services, today announced the release of East® version 6.4. East®, the life science industry's leading clinical trial design platform, will deliver expanded functionality to support the application of groundbreaking methods including multi-arm multi-stage designs, and dual agent dose escalation designs for combination therapies. With ever-increasing pressure on the industry to improve R&D productivity and reduce Phase 3 failure rates, uptake of adaptive designs is set to rise [1]. The innovative designs incorporated in the 6.4 release address key pain points of sponsors and researchers looking to apply advanced statistical strategies with potential to accelerate development. "Our goal is to enable the implementation of cutting-edge, published statistical methods and ultimately increase our customers' chances of success in clinical development," said Yannis Jemiai, Ph.D., Vice President of Cytel. "Statisticians rely on East® to simplify the application of complex approaches, within a trusted, validated environment. The East® 6.4 release represents our commitment to meeting the evolving needs of our clients, and is the result of extensive work by our software development team as well as ongoing collaboration with industry sponsors and academic researchers." The enhanced capabilities span three modules:
East® MAMS
East® ESCALATE
East® PREDICT
About East®
For East® product or sales queries from existing or prospective
customers contact: About Cytel At Cytel, we're shaping the future of drug development. Our cutting-edge software and biometrics outsourcing services enable pharmaceutical and biotechnology companies of all sizes to improve clinical success rates. [1]"Tufts CSDD Report: Drugmakers Modifying R&D To Temper Health Care Costs While Upping Productivity - MedCity News". MedCity News. N.p., 2015. Web. 12 May 2016.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160524005747/en/ |